Molecular Indicators of Prognosis and Response to Therapy in Breast Cancer

To assay gene expression in 50 donated tissue from breast tumors in the MMC repository to further explore tumor types, and their clinical subtypes. Initial experiments, previously supported by Maine Cancer Foundation, identifies a relatively small subset (less than 200) of gene expression changes that classify breast cancers into 5 clinical subtypes with distinct differences in overall prognosis and response to common chemotherapeutic agents. This additional funding will refine this search and reduce the 'candidate gene' list to 10-20 markers that recapitulate these classes reproducibly, and which can be modified to create a rapidly applicable clinical lab test using conventional lab methodology.

Organization: 
Maine Center for Cancer Medicine
Researcher: 
Karen Rasmussen, Ph. D
Grant Amount Given: 
$60,700
Year Issued: 
2003
Period: 
Annual
Grant Category: 
Research
Types of Cancer: 
Breast
Grant Duration: 
1 Year Pilot Grant

Maine Cancer Foundation Grants to this Organization:

Year Program Amount Category Organization
2010 Evaluating MicroRNA's as Prognostic Determinants in Stage II Colon Cancer $78,000 Research Maine Center for Cancer Medicine
2008 Colorectal Cancer Screenings $6,839 Screening Maine Center for Cancer Medicine
2007 Toolkit for Colorectal Cancer $4,800 Education Maine Center for Cancer Medicine
2006 Cancer Risk and Prevention $1,862 Education Maine Center for Cancer Medicine
2006 Molecular Predictors of Iressa Response in Lung Cancer Patients $68,241 Research Maine Center for Cancer Medicine
2004 Molecular Markers of Prognosis and Response to Therapy in Breast Cancer $70,500 Research Maine Center for Cancer Medicine
2003 Molecular Indicators of Prognosis and Response to Therapy in Breast Cancer $60,700 Research Maine Center for Cancer Medicine
2001 Cancer Genetics Research $87,000 Research Maine Center for Cancer Medicine